Plasma carnitine ester profiles in Crohn's disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes

British Journal of Nutrition

Volumn 98, Issue 2, 2007, Pages 345-350

  Bene, Judit ^a   Komlósi, Katalin ^a   Magyari, Lili ^a   Talián, Gábor ^a   Horváth, Krisztina ^a   Gasztonyi, Beáta ^a   Miheller, Pál ^b   Figler, Mária ^a   Mózsik, Gyula ^a   Tulassay, Zsolt ^b   Melegh, Béla ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Carnitine ester profile; Crohn's disease; NOD2 CARD15; OCTN1; OCTN2

Indexed keywords

CARNITINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYTOSINE; GUANINE; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PROPIONYLCARNITINE; TYROSINE;

ADULT; AGED; AMINO ACID METABOLISM; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIET RESTRICTION; ELECTROSPRAY MASS SPECTROMETRY; ENVIRONMENTAL FACTOR; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREVALENCE; QUADRUPOLE MASS SPECTROMETRY; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARNITINE; CROHN DISEASE; ESTERS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; ORGANIC CATION TRANSPORT PROTEINS;

EID: 34447624497     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114507705020     Document Type: Article

References (33)

1. Adlouni HA, Katrib K & Ferard G (1988) Changes in carnitine in polymorphonuclear leukocytes, mononuclear cells, and plasma from patients with inflammatory disorders. Clin Chem 34, 40-43.
2. Ahmad T, Armuzzi A, Bunce M, et al. (2002) The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 122, 854-866.
3. Arnott ID, Nimmo ER, Drummond HE, et al. (2004) NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun 5 417-425.
4. Bene J. Komlosi K, Gasztonyi B, Juhasz M, Tulassay Z & Melegh B (2005) Plasma carnitine ester profile in adult celiac disease patients maintained on long-term gluten free diet. World J Gastroenterol 11, 6671-6675.
5. Bieber LL (1988) Carnitine. Annu Rev Biochem 57, 261-283.
6. Brant SR, Picco MF, Achkar JP, et al. (2003) Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis 9, 281-289.
7. Bremer J (1983) Carnitine-metabolism and functions. Physiol Rev 63, 1420-1480.
8. Costa CC, de Almeida IT, Jakobs C, Poll-The BT & Duran M (1999) Dynamic changes of plasma acylcarnitine levels induced by fasting and sunflower oil challenge test in children. Pediatr Res 46, 440-444.
9. Demirkol M. Sewell AC & Bohles H (1994) The variation of carnitine content in human blood cells during disease - a study in bacterial infection and inflammatory bowel disease. Eur J Pediatr 153, 565-568.
10. Di Sabatino A, Morera R, Ciccocioppo F, Cazzola P, Gotti S, Tinozzi FP, Tinozzi S & Corazza GR (2005) Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol Ther 22, 789-794.
11. Fritz IB & Yue KT (1963) Long-chain carnitine acyltransferase and the role of acylcarnitine derivatives in the catalytic increase of fatty acid oxidation induced by carnitine. J Lipid Res 4, 279-288.
12. Hampe J, Cuthbert A, Croucher PJ, et al. (2001) Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357, 1925-1928.
13. Hugot JP, Chamaillard M. Zouali H, et al. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603.
14. Inoue N. Tamura K, Kinouchi Y, et al. (2002) Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 123, 86-91.
15. Leong RW, Armuzzi A, Ahmad T, Wong ML, Tse P, Jewell DP & Sung JJ (2003) NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment Pharmacol Ther 17, 1465-1470.
16. Lesage S, Zouali H, Cezard JP, et al. (2002) CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 70, 845-857.
17. Melegh B, Kerner J & Bieber LL (1987) Pivampicillin-promoted. excretion of pivaloylcarnitine in humans. Biochem Pharmacol 36, 3405-3409.
18. Mendoza JL, Murillo LS, Fernandez L, Pena AS, Lana R, Urcelay E, Cruz-Santamaria DM, de la Concha EG, Diaz-Rubio M & Garcia-Paredes J (2003) Prevalence of mutations of the NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn disease. Scand J Gastroenterol 38, 1235-1240.
19. Newman B, Gu X, Wintle R, Cescon D, Yazdanpanah M, Liu X, Peltekova V, Van Oene M, Amos CI & Siminovitch KA (2005) A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. Gastroenterology 128, 260-269.
20. Noble CL, Nimmo ER, Drummond H, Ho GT, Tenesa A, Smith L, Anderson N, Arnott ID & Satsangi J (2005) The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology 129, 1854-1864.
21. Ogura Y, Bonen DK, Inohara N, et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606.
22. Peltekova VD, Wintle RF, Rubin LA, et al. (2004) Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 36, 471-475.
23. Rashed MS (2001) Clinical applications of tandem mass spectrometry: Ten years of diagnosis and screening for inherited metabolic diseases. J Chromatogr B Biomed Sci Appl 758, 27-48.
24. Schreiber S, Nikolaus S & Hampe J (1998) Activation of nuclear factor kappa B inflammatory bowel disease. Gut 42, 477-494.
25. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottiere HM & Galmiche JP (2000) Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 47, 397-403.
26. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y & Tsuji A (1998) Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273, 20378-20382.
27. Torok HP, Glas J, Tonenchi L, et al. (2005) Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut 54, 1421-1427.
28. Vermeire S, Pierik M, Hlavaty T, et al. (2005) Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. Gastroenterology 129, 1845-1853.
29. Vermeire S, Wild G, Kocher K, et al. (2002) CARD15 genetic variation in a Quebec population: Prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 71, 74-83.
30. Vind I, Vieira A, Hougs L, et al. (2005) NOD2/CARD15 gene polymorphisms in Crohn's disease: A genotype-phenotype analysis in Danish and Portuguese patients and controls. Digestion 72, 156-163.
31. Yamazaki K, Takazoe M, Tanaka T, Ichimori T, Saito S, Iida A, Onouchi Y, Hata A & Nakamura Y (2004) Association analysis of SLC22A4, SLC22A5 and DLG5 in Japanese patients with Crohn disease. J Hum Genet 49 664-668.
32. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH & Ganapathy V (2000) Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta 1466, 315-327.
33. Wu X, Prasad PD, Leibach FH & Ganapathy V (1998) cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun 246, 589-595.